Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. Class ASSE: 603707

Announcement on Approval of Subsidiary's Product Dalbavancin for Injection by the U.S. FDA

· Issued by Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. Class A via Shanghai Stock Exchange
Announcement on Approval of Subsidiary's Product Dalbavancin for Injection by the U.S. FDA

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment